Pacific Edge ranked number 5 in inaugural Financial Times FT 1000 High Growth Companies Asia-Pacific
Pacific Edge Limited is delighted to have been ranked number 5 in the inaugural Financial Times FT 1000 High Growth Companies Asia-Pacific
Pacific Edge is the only health company and one of only three New Zealand companies in the top 10.
CEO, David Darling, says “This is a reflection of our triple-digit revenue growth over the past three years as we have focused on building our suite of highly accurate, non-invasive Cxbladder tests for the detection and management of bladder cancer. We remain focused on building traction in the global market, particularly the United States, and enabling better care and outcomes for patients."
The ranking follows on the heels of Pacific Edge’s 20th ranking in the 2017 Deloitte Fast50 in November, 171st ranking in the Deloitte Asia Pacific Technology Fast500 in December and its inclusion in the TIN Top Ten Hot Emerging Companies in October 2017.
For more information on selection methodologies of the FT 1000 High Growth Companies Asia Pacific and Deloitte Asia Pacific Technology Fast500, see this comparison chart.« Back